𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552

✍ Scribed by Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
481 KB
Volume
16
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and 7 PR) with a median duration of response of 2.5 months. Myelosuppression was dose-limiting. Hemorrhagic cystitis was observed in three patients (10%). Nausea and vomiting was generally mild or moderate. One patient developed transient neurotoxic symptoms with confusion and disorientation. An additional patient developed an anaphylactic-type reaction with shortness of breath and respiratory strider during the fourth course of therapy. Ifosfamide, as a single agent, produces remissions of limited duration in non-Hodgkin's lymphoma in patients in second or third relapse.

πŸ“œ SIMILAR VOLUMES

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day Γ— 3) with mesna (400 mg/m^2^ intravenously q 4 h daily Γ— 3) was combined with mitoxantrone (14 mg/m^2^ intravenously Γ— 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351
✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated

A southwest oncology group and cancer an
A southwest oncology group and cancer and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in Adults with advanced osteosarcoma, ewing's sarcoma, and rhabdomyosarcoma
✍ Karen Antman; John Crowley; Stanley P. Balcerzak; Raymond A. Kempf; Raymond B. W πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 102 KB πŸ‘ 3 views

sarcoma, or osteosarcoma. ## Results . Between 1987-1991, 81 patients were entered; 69 patients were eligible.

Phase II trial of etoposide and cis-diam
Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and leukemia group B (CALGB) study 8353
✍ Rybak, Mary Ellen ;McCarroll, Kathleen ;Kaplan, Richard J. ;Propert, Kathleen J. πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 394 KB

## Abstract A phase II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed Hodgkin's disease (HD) to assess the activity of the combination of etoposide and cis‐platin. Twenty‐seven patients were entered; 22 were evaluated for this report. Treatme

Phase II trial of cis-dichlorodiamminepl
Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B
✍ F. Cavalli; Dr. W. F. Jungi; N. I. Nissen; T. F. Pajak; M. Coleman; J. F. Hollan πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 279 KB πŸ‘ 3 views

In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(l1) (cis-platinum) once every three weeks. All patients had received extensive prior therapy. Partial remission was obtai